{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:00:34Z","timestamp":1791896434460,"version":"4.3.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.omton.2024.200797","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T08:50:13Z","timestamp":1711097413000},"page":"200797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["CAR\u2019TCR-T cells co-expressing CD33-CAR and dNPM1-TCR as superior dual-targeting approach for AML treatment"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2645-6781","authenticated-orcid":false,"given":"Karin","family":"Teppert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella Elias","family":"Yonezawa Ogusuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Brandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Herbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Werchau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Khorkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"W\u00f6hle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nojan","family":"Jelveh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Bisdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Engels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"K\u00fcnkele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3056-4582","authenticated-orcid":false,"given":"Dominik","family":"Lock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2024.200797_bib1","doi-asserted-by":"crossref","first-page":"927153","DOI":"10.3389\/fimmu.2022.927153","article-title":"CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2024.200797_bib2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3390\/cancers14030497","article-title":"Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia","volume":"14","author":"Marvin-Peek","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2024.200797_bib3","first-page":"38","article-title":"Acute Myeloid Leukemia: A Review","volume":"103","author":"Pelcovits","year":"2020","journal-title":"R.\u00a0I. Med. J."},{"key":"10.1016\/j.omton.2024.200797_bib4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s12185-018-2412-8","article-title":"Hematopoietic stem cell transplantation for acute myeloid leukemia","volume":"107","author":"Takami","year":"2018","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.omton.2024.200797_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","article-title":"Catch me if you can: how AML and its niche escape immunotherapy","volume":"36","author":"Tettamanti","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2024.200797_bib6","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.ymthe.2020.05.021","article-title":"Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System","volume":"28","author":"Rotiroti","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2024.200797_bib7","series-title":"The Black Hole: CAR T Cell Therapy in AML 15","author":"Atilla","year":"2023"},{"key":"10.1016\/j.omton.2024.200797_bib8","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/leu.2015.52","article-title":"CD33-specific chimeric antigen receptor T\u00a0cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2024.200797_bib9","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omton.2024.200797_bib10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.omto.2022.04.003","article-title":"Chimeric anti-GPC3 sFv-CD3epsilon receptor-modified T\u00a0cells with IL7 co-expression for the treatment of solid tumors","volume":"25","author":"Sun","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2024.200797_bib11","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.3390\/cancers14092182","article-title":"Dissecting the Genetic and Non-Genetic Heterogeneity of Acute Myeloid Leukemia Using Next-Generation Sequencing and In\u00a0Vivo Models","volume":"14","author":"Desai","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2024.200797_bib12","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.3390\/cancers13133214","article-title":"CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin","volume":"13","author":"Molica","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2024.200797_bib13","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2018-99-110579","article-title":"First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: Update on Phase 1 Clinical Trial","volume":"132","author":"Liu","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.omton.2024.200797_bib14","doi-asserted-by":"crossref","first-page":"695051","DOI":"10.3389\/fimmu.2021.695051","article-title":"Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia","volume":"12","author":"Limongello","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2024.200797_bib15","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2024.200797_bib16","doi-asserted-by":"crossref","first-page":"787108","DOI":"10.3389\/fonc.2022.787108","article-title":"Antigen-Specific TCR-T Cells for Acute Myeloid Leukemia: State of the Art and Challenges","volume":"12","author":"Kang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2024.200797_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omton.2024.200797_bib18","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omton.2024.200797_bib19","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1172\/JCI97482","article-title":"Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia","volume":"129","author":"Van der Lee","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omton.2024.200797_bib20","doi-asserted-by":"crossref","first-page":"14563","DOI":"10.3390\/ijms232314563","article-title":"Joining Forces for Cancer Treatment: From \"TCR versus CAR\" to \"TCR and CAR\"","volume":"23","author":"Teppert","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2024.200797_bib21","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3389\/fonc.2018.00539","article-title":"A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia","volume":"8","author":"Schneider","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2024.200797_bib22","doi-asserted-by":"crossref","first-page":"101224","DOI":"10.1016\/j.omtm.2024.101224","article-title":"Automated manufacture of \u0394NPM1 TCR-engineered T\u00a0cells for AML therapy","volume":"32","author":"Elias Yonezawa Ogusuku","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omton.2024.200797_bib23","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/bioinformatics\/btl140","article-title":"Improved scoring of functional groups from gene expression data by decorrelating GO graph structure","volume":"22","author":"Alexa","year":"2006","journal-title":"Bioinformatics"},{"key":"10.1016\/j.omton.2024.200797_bib24","doi-asserted-by":"crossref","first-page":"D691","DOI":"10.1093\/nar\/gkq1018","article-title":"Reactome: a database of reactions, pathways and biological processes","volume":"39","author":"Croft","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omton.2024.200797_bib25","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1039\/C5MB00663E","article-title":"ReactomePA: an R\/Bioconductor package for reactome pathway analysis and visualization","volume":"12","author":"Yu","year":"2016","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.omton.2024.200797_bib26","doi-asserted-by":"crossref","first-page":"e28208","DOI":"10.4161\/sgtp.28208","article-title":"Rho-GTPases as key regulators of T lymphocyte biology","volume":"5","author":"Saoudi","year":"2014","journal-title":"Small GTPases"},{"key":"10.1016\/j.omton.2024.200797_bib27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1189\/jlb.69.3.317","article-title":"Molecular motors involved in T\u00a0cell receptor clusterings","volume":"69","author":"Krawczyk","year":"2001","journal-title":"J.\u00a0Leukoc. Biol."},{"key":"10.1016\/j.omton.2024.200797_bib28","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1200\/JCO.2007.15.9764","article-title":"Long-Term Disease-Free Survival After Gemtuzumab, Intermediate-Dose Cytarabine, and Mitoxantrone in Patients With CD33+ Primary Resistant or Relapsed Acute Myeloid Leukemia","volume":"26","author":"Chevallier","year":"2008","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omton.2024.200797_bib29","doi-asserted-by":"crossref","first-page":"e003149","DOI":"10.1136\/jitc-2021-003149","article-title":"Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T\u00a0cell immunotherapy for acute myeloid leukemia defines optimized construct design","volume":"9","author":"Qin","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omton.2024.200797_bib30","doi-asserted-by":"crossref","first-page":"1152457","DOI":"10.3389\/fimmu.2023.1152457","article-title":"Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis","volume":"14","author":"Shahzad","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2024.200797_bib31","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ni1191","article-title":"T cell costimulation by chemokine receptors","volume":"6","author":"Molon","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omton.2024.200797_bib32","doi-asserted-by":"crossref","first-page":"608484","DOI":"10.3389\/fcell.2020.608484","article-title":"Single-Molecule, Super-Resolution, and Functional Analysis of G Protein-Coupled Receptor Behavior Within the T Cell Immunological Synapse","volume":"8","author":"Felce","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omton.2024.200797_bib33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/08923973.2018.1434792","article-title":"The essential role of G protein-coupled receptor (GPCR) signaling in regulating T\u00a0cell immunity","volume":"40","author":"Wang","year":"2018","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.omton.2024.200797_bib34","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1002\/eji.200838195","article-title":"The heterotrimeric G-protein alpha-subunit Galphaq regulates TCR-mediated immune responses through an Lck-dependent pathway","volume":"38","author":"Ngai","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.omton.2024.200797_bib35","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41551-023-01037-x","article-title":"Stable expression of large transgenes via the knock-in of an integrase-deficient lentivirus","volume":"7","author":"Chavez","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.omton.2024.200797_bib36","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.3390\/ijms21103643","article-title":"High-Capacity Adenoviral Vectors: Expanding the Scope of Gene Therapy","volume":"21","author":"Ricobaraza","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2024.200797_bib37","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in\u00a0vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2024.200797_bib38","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1182\/blood-2003-05-1620","article-title":"A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia","volume":"102","author":"Kell","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.omton.2024.200797_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.omto.2023.100751","article-title":"Bispecific CD33\/CD123 targeted chimeric antigen receptor T\u00a0cells for the treatment of acute myeloid leukemia","volume":"31","author":"Boucher","year":"2023","journal-title":"Mol. Therapy - Oncolytics"},{"key":"10.1016\/j.omton.2024.200797_bib40","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1182\/blood-2023-180890","article-title":"CD33-TIM3 Dual CAR T Cells: Enhancing Specificity While Maintaining Efficacy Against AML","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2024.200797_bib41","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fcell.2019.00233","article-title":"Doxycycline Inducible Chimeric Antigen Receptor T Cells Targeting CD147 for Hepatocellular Carcinoma Therapy","volume":"7","author":"Zhang","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omton.2024.200797_bib42","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.omton.2024.200797_bib43","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/ijc.33865","article-title":"CD33-directed immunotherapy with third-generation chimeric antigen receptor T\u00a0cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells","volume":"150","author":"Liu","year":"2022","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omton.2024.200797_bib44","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.3390\/cancers13215390","article-title":"An HLA-A\u221711:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML","volume":"13","author":"van der Lee","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2024.200797_bib45","doi-asserted-by":"crossref","first-page":"100156","DOI":"10.1016\/j.xpro.2020.100156","article-title":"An Improved Protocol for Establishment of AML Patient-Derived Xenograft Models","volume":"1","author":"Hassan","year":"2020","journal-title":"STAR Protoc."},{"key":"10.1016\/j.omton.2024.200797_bib46","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1089\/hum.2017.111","article-title":"Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use","volume":"28","author":"Lock","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omton.2024.200797_bib47","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.omton.2024.200797_bib48","author":"Kolde"}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329924000390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329924000390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:19:29Z","timestamp":1765804769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329924000390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2950329924000390"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2024.200797","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR\u2019TCR-T cells co-expressing CD33-CAR and dNPM1-TCR as superior dual-targeting approach for AML treatment","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2024.200797","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"200797"}}